• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

    2/9/23 11:07:47 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email
    SC 13G/A 1 tv0339-atossatherapeuticsinc.htm SCHEDULE 13G/A atossatherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Atossa Therapeutics Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  04962H506

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  04962H506

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    5,651,187

    8.  SHARED DISPOSITIVE POWER

    46,349

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,697,536

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.50%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Atossa Therapeutics Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    107 Spring Street
    Seattle, WA 98104

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    04962H506

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ATOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      3/28/25 4:00:03 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Galli Stephen J

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      7/1/24 4:00:06 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Steinhart Richard I

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      7/1/24 4:00:11 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

      Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer. ATOS) i

      5/14/25 8:15:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

      Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

      5/13/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

      SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations. The newly granted patent includes 58 claims covering (Z)-endoxifen formulations, including various levels of purity and stability as well as methods of using those formulations. This patent provides additio

      4/30/25 8:45:06 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Atossa Therapeutics Inc.

      10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      5/13/25 8:15:19 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      5/13/25 8:05:08 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      4/7/25 4:05:13 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12

      11/12/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

      SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial

      11/5/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

      SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t

      8/20/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      3/28/25 4:00:03 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      4/11/24 4:05:09 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      11/12/24 1:32:30 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      11/4/24 11:27:58 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      2/9/23 11:07:47 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Financials

    Live finance-specific insights

    See more
    • Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

      Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

      5/13/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

      Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

      3/25/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-

      3/20/25 9:13:10 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care